SCHEMBL2016737

SCHEMBL2016737

CNc1nc2ccccc2[nH]1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.61
PKM P14618 4/20 0.58
RAB9A P51151 9/20 0.57
NPC1 O15118 8/20 0.57
SMN1; SMN2 Q16637 7/20 0.57
MAPT P10636 3/20 0.57
BCHE P06276 1/20 0.57
TRPC3 Q13507 1/20 0.57
TRPC4 Q9UBN4 1/20 0.57
TRPC5 Q9UL62 1/20 0.57
TP53 P04637 3/20 0.56
CYP3A4 P08684 1/20 0.56
ALDH1A1 P00352 3/20 0.54
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
GAA P10253 2/20 0.54
HPGD P15428 1/20 0.54
ALOX15 P16050 1/20 0.54
NPSR1 Q6W5P4 2/20 0.54
HSD17B10 Q99714 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29502497 1.00 LMNA (0.61) LMNAPKMRAB9ANPC1SMN1; SMN2
Hydrochloric Acid SCHEMBL30192728 0.98 PKM (0.61) LMNAPKMRAB9ANPC1SMN1; SMN2
Hydrochloric Acid SCHEMBL29117384 0.98 PKM (0.61) LMNAPKMRAB9ANPC1SMN1; SMN2
Hydrochloric Acid SCHEMBL27726840 0.98 PKM (0.61) LMNAPKMRAB9ANPC1SMN1; SMN2
SCHEMBL8729265 0.84 LMNA (0.57) LMNAPKMRAB9ANPC1SMN1; SMN2
SCHEMBL28050241 0.83 RAB9A (0.68) LMNAPKMRAB9ANPC1SMN1; SMN2
SCHEMBL28728369 0.81 RAB9A (0.66) LMNAPKMRAB9ANPC1SMN1; SMN2
SCHEMBL14380967 0.79 CYP3A4 (0.61) LMNAPKMRAB9ANPC1SMN1; SMN2
SCHEMBL1800355 0.79 CYP3A4 (0.61) LMNAPKMRAB9ANPC1SMN1; SMN2
SCHEMBL29647608 0.79 CYP3A4 (0.61) LMNAPKMRAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 213 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116836382-A Halogen-free antibacterial polyamide and preparation method thereof 四川轻化工大学 2023-10-03 CN claimed
CN-106337196-B Microscopic void sealer for the processing of printed wiring board precious metal surface 深圳市贝加电子材料有限公司 2018-08-10 CN claimed
CN-106337196-A Micro pore sealing agent for noble metal surface treatment of printed circuit board 深圳市贝加电子材料有限公司 2017-01-18 CN claimed
EP-2445346-A1 OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE Genentech, Inc. (US) 2012-05-02 EP claimed
WO-2010151601-A1 OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2010-12-29 WO claimed
EP-1451160-B1 PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN ICAGEN INC (US) 2010-01-13 EP claimed
CN-1034216-C 7-(substituted)-9-[(substituted glycyl) amido]-6-demethyl-6-deoxytetracyclines AMERICAN CYANAMID CO (US) 1997-03-12 CN claimed
EP-0594656-A1 4-AMINO-3-HYDROXYCARBOXYLIC ACID DERIVATIVES SANDOZ LTD. (CH) 1994-05-04 EP claimed
CN-1083805-A 7-(replacement)-9-[(substituted glycyl) amido]-6-demethylation-6-deoxytetra cycline AMERICAN CYANAMID CO (US) 1994-03-16 CN claimed
WO-1993001166-A1 4-AMINO-3-HYDROXYCARBOXYLIC ACID DERIVATIVES SANDOZ LTD. (CH) 1993-01-21 WO claimed
US-12435095-B2 Substituted morpholines as ATR kinase inhibitors SHANGHAI ANNOVA BIOTECHNOLOGY CO., LTD. (CN) 2025-10-07 US disclosed
US-20250051362-A1 SUBSTITUTED FUSED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI ANNOVA BIOTECHNOLOGY CO., LTD. (CN) 2025-02-13 US disclosed
EP-4455144-A1 SUBSTITUTED FUSED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Annova Biotechnology Co., Ltd. (CN) 2024-10-30 EP disclosed
CN-117751127-A Five-membered nitrogen-containing heterocyclic heteroaryl derivative and application thereof 南京大美生物制药有限公司 2024-03-22 CN disclosed
WO-2024017897-A1 1,3,4-OXADIAZOLE DERIVATIVES AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS ITALFARMACO S.P.A. (IT) 2024-01-25 WO disclosed
US-5760029-A TREATING CANCER METASTASIS, DIABETIC RETINOPATHY, NEOVASCULAR GLAUCOMA, THROMBOSIS, RESTENOSIS, OSTEOPOROSIS, MACULAR DEGENERATION THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1998-06-02 US disclosed
CN-1034216-C 7-(substituted)-9-[(substituted glycyl) amido]-6-demethyl-6-deoxytetracyclines AMERICAN CYANAMID CO (US) 1997-03-12 CN disclosed
CN-1087626-A The glycyl that novel 7-(replacement)-8-(replacement)-9-[(replaces) amido]-6-demethyl-6-deoxidation tsiklomitsin AMERICAN CYANAMID CO (US) 1994-06-08 CN disclosed
CN-1083805-A 7-(replacement)-9-[(substituted glycyl) amido]-6-demethylation-6-deoxytetra cycline AMERICAN CYANAMID CO (US) 1994-03-16 CN disclosed
US-4167569-A ANTICOAGULANTS IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) 1979-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12435095-B2 Substituted morpholines as ATR kinase inhibitors ATR, WEE1, WEE2 LMNA 2546/4885PKM 1002/4885RAB9A 2504/4885
US-20250051362-A1 SUBSTITUTED FUSED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF WEE1, ATR, WEE2 LMNA 2829/4885PKM 2313/4885RAB9A 1862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.